1) Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL:2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J 2:76-82, 2013
2) Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Anthony Price D, On behalf of the KIGS international board:Recurrence of brain tumours in patients treated with growth hormone:analysis of KIGS(Pfizer International Growth Database). Acta Paediatr 95:1284-1290, 2006
3) Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A;Pasireotide C2402 Study Group:Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly(PAOLA):a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875-884, 2014
4) Jung C, Inder WJ:Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust 188:409-413, 2008
5) Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA;Endocrine Society:Acromegaly:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99:3933-3951, 2014
6) Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA;Endocrine society:Diagnosis and treatment of hyperprolactinemia:an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273-288, 2011
7) Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM;Pasireotide B2305 Study Group:Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease:results from a phase Ⅲ study. Clin Endocrinol(Oxf)81:408-417, 2014